



## ASX Announcement

### Race further strengthens Clinical Advisory Board

- Eminent haematology oncologist Professor Didier Blaise joins Race's Clinical Advisory Board
- Prof. Blaise's expertise will be instrumental to the success of the Company's 5 path strategy

---

**10 March 2020** – Race Oncology Limited (ASX: RAC) is pleased to announce that it has continued to strengthen its Clinical Advisory Board (CAB) with the appointment of the leading international haematology oncologist, Professor Didier Blaise.

Didier Blaise is Professor of Medicine at the Aix-Marseille University in Marseille, France and has a number of additional prestigious appointments (see 'Detailed background Prof. Didier Blaise'). He has conducted numerous national and international clinical trials in the field of hematopoietic stem cell transplantation and oncology and is the author of more than 500 peer reviewed papers in the field of haematology oncology.

Along with Prof. Jaap Boelens and under the leadership of Prof. Borje Andersson, Prof. Blaise will play a critical role in the implementation of RAC's 5-Path clinical strategy.

**Commentary:**

**Prof. Borje Andersson, Chair of the RAC CAB:**

"It is with utmost pleasure and excitement that I welcome Professor Blaise to the Race Oncology Clinical Advisory Board. His expertise in clinical haematology and pharmacology as well immunology, paired with his deep, first-hand knowledge of all facets of the problems facing clinical oncologists will be extremely important in complementing the existing expertise of our team. We anticipate his contributions to significantly strengthen our 5-path program of clinical trials."

**Prof. Didier Blaise:**

"I really look forward to working with the clinical advisory board at Race on the development of new, improved combination regimens based on bisantrene for both children with high-risk acute leukaemia, and adults with leukaemia and solid tumours. This program promises to become more efficient, yet less toxic than previously available treatments, and the patients' fight against cancer may now for the first time be relieved from the risk of suffering long-lasting and devastating heart failure as the price for successfully conquering a malignant disease."

- ENDS -

**Detailed background Prof. Didier Blaise:**

Prof. Blaise is Professor of Medicine at the Aix-Marseille University in Marseille, France and Chairman of the Marseille University Hematology Department at Institute Paoli Calmettes. He has been the leader of the Blood and Marrow Transplantation and Immune Cellular Therapy program at Institute Paoli Calmettes since 1991. This program is one of the most active in Europe, with more than 8800 transplants conducted. Prof. Blaise is also the program leader of the Transplant and Cellular Immunotherapy program in the INSERM, the Tumor Immunology team of the Cancer Research Center of Marseilles (CRCM), and the President of the Medical Council of Institute Paoli Calmettes in Marseilles.

In addition, Professor Blaise was a founding member and former President of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and is an active member of numerous international haematology and oncology scientific societies, notably EBMT, EHA, ASH, ASCO, ASTCT and ISEH.

Prof. Blaise has conducted numerous national and international clinical trials in the field of hematopoietic stem cell transplantation and oncology, the author or co-author of more than 500 peer reviewed papers, and the recipient of many national grants.

His research interests focus on clinical transplantation, dose intensity of conditioning regimens, immunomodulation after allogeneic transplantation, immunotherapy and cellular immunotherapy of hematologic malignancies and solid tumours, and the economic and social impact of innovation in these clinical areas.

**About Race Oncology (RAC: ASX)**

Race Oncology (RAC) is a drug development biotech with a Phase II cancer drug called Bisantrone. RAC has compelling clinical data for Bisantrone in acute myeloid leukaemia (AML) as well as breast and ovarian cancer. RAC is pursuing an exciting '5-Path' clinical development strategy that involves parallel US and Australian clinical trials in AML, breast and ovarian with clinical trials to begin in 2020.

Release authorised by:

Peter Molloy, Managing Director

plmolloy@raceoncology.com

Media contact:

Heidi Cuthbert

+61 411 272 366

heidi.cuthbert@multiplier.com.au

**Released through:** Henry Jordan, Six Degrees Investor Relations: +61 (0) 431 271 538